Publications

Export 89 results:
Auteur Title [ Type(Asc)] Année
Filtres: Auteur is Gauthier, Serge  [Enlever les filtres]
Journal Article
Belleville S, Gauthier S, Lepage E, Kergoat M-J, Gilbert B.  2014.  Predicting decline in mild cognitive impairment: a prospective cognitive study.. Neuropsychology. 28(4):643-52.
Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K et al..  2016.  Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.. Alzheimers Dement. 12(3):292-323.
Wilcock GK, Gauthier S, Frisoni GB, Jia J, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Schelter BO, Wischik DJ et al..  2018.  Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.. J Alzheimers Dis. 61(1):435-457.
Hye A, Riddoch-Contreras J, Baird AL, Ashton NJ, Bazenet C, Leung R, Westman E, Simmons A, Dobson R, Sattlecker M et al..  2014.  Plasma proteins predict conversion to dementia from prodromal disease.. Alzheimers Dement. 10(6):799-807.e2.
Cloutier S, Chertkow H, Kergoat M-J, Gauthier S, Belleville S.  2015.  Patterns of Cognitive Decline Prior to Dementia in Persons with Mild Cognitive Impairment.. J Alzheimers Dis. 47(4):901-13.
Gauthier S, Herrmann N, Rosa-Neto P.  2018.  Optimal use of cholinergic drugs in Alzheimer's disease.. Brain.
Hadoux X, Hui F, Lim JKH, Masters CL, Pébay A, Chevalier S, Ha J, Loi S, Fowler CJ, Rowe C et al..  2019.  Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease.. Nat Commun. 10(1):4227.
Ng KPin, Pascoal TA, Mathotaarachchi S, Chung C-O, Benedet AL, Shin M, Kang MSu, Li X, Ba M, Kandiah N et al..  2017.  Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.. Neurology. 88(19):1814-1821.
Parent MJ, Zimmer ER, Shin M, Kang MSu, Fonov VS, Mathieu A, Aliaga A, Kostikov A, Carmo SDo, Dea D et al..  2017.  Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities.. J Neurosci. 37(50):12263-12271.
Bergeron D, Flynn K, Verret L, Poulin S, Bouchard RW, Bocti C, Fülöp T, Lacombe G, Gauthier S, Nasreddine Z et al..  2017.  Multicenter Validation of an MMSE-MoCA Conversion Table.. J Am Geriatr Soc. 65(5):1067-1072.
Ng KPin, Pascoal TA, Mathotaarachchi S, Therriault J, Kang MSu, Shin M, Guiot M-C, Guo Q, Harada R, Comley RA et al..  2017.  Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain.. Alzheimers Res Ther. 9(1):25.
Petersen RC, Caracciolo B, Brayne C, Gauthier S, Jelic V, Fratiglioni L.  2014.  Mild cognitive impairment: a concept in evolution.. J Intern Med. 275(3):214-28.
Ismail Z, Agüera-Ortiz L, Brodaty H, Cieslak A, Cummings J, Fischer CE, Gauthier S, Geda YE, Herrmann N, Kanji J et al..  2017.  The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations.. J Alzheimers Dis. 56(3):929-938.
Zimmer ER, Parent MJ, A Cuello C, Gauthier S, Rosa-Neto P.  2014.  MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research.. Trends Neurosci. 37(11):629-41.
Bier N, Grenier S, Brodeur C, Gauthier S, Gilbert B, Hudon C, Lepage E, Ouellet M-C, Viscogliosi C, Belleville S.  2015.  Measuring the impact of cognitive and psychosocial interventions in persons with mild cognitive impairment with a randomized single-blind controlled trial: rationale and design of the MEMO+ study.. Int Psychogeriatr. 27(3):511-25.
Zimmer ERigon, Leuzy A, Bhat V, Gauthier S, Rosa-Neto P.  2014.  In vivo tracking of tau pathology using positron emission tomography (PET) molecular imaging in small animals.. Transl Neurodegener. 3(1):6.
Pascoal TA, Shin M, Kang MSu, Chamoun M, Chartrand D, Mathotaarachchi S, Bennacef I, Therriault J, Ng KPin, Hopewell R et al..  2018.  In vivo quantification of neurofibrillary tangles with [F]MK-6240.. Alzheimers Res Ther. 10(1):74.
Leuzy A, Zimmer ERigon, Dubois J, Pruessner J, Cooperman C, Soucy J-P, Kostikov A, Schirmaccher E, Désautels R, Gauthier S et al..  2015.  In vivo characterization of metabotropic glutamate receptor type 5 abnormalities in behavioral variant FTD.. Brain Struct Funct.
Zimmer ER, Parent MJ, Leuzy A, Aliaga A, Aliaga A, Moquin L, Schirrmacher ES, Soucy J-P, Skelin I, Gratton A et al..  2015.  Imaging in vivo glutamate fluctuations with [(11)C]ABP688: a GLT-1 challenge with ceftriaxone.. J Cereb Blood Flow Metab. 35(7):1169-74.
Leuzy A, Zimmer ERigon, Bhat V, Rosa-Neto P, Gauthier S.  2014.  Imaging biomarkers for amyloid: a new generation of probes and what lies ahead.. Int Psychogeriatr. 26(5):703-7.
Mathotaarachchi S, Pascoal TA, Shin M, Benedet AL, Kang MSu, Beaudry T, Fonov VS, Gauthier S, Rosa-Neto P.  2017.  Identifying incipient dementia individuals using machine learning and amyloid imaging.. Neurobiol Aging. 59:80-90.
Gauthier S, Leuzy A, Rosa-Neto P.  2014.  How can we improve transfer of outcomes from randomized clinical trials to clinical practice with disease-modifying drugs in Alzheimer's disease? Neurodegener Dis. 13(2-3):197-9.
Schoemaker D, Buss C, Head K, Sandman CA, Davis EP, M Chakravarty M, Gauthier S, Pruessner JC.  2016.  Hippocampus and amygdala volumes from magnetic resonance images in children: Assessing accuracy of FreeSurfer and FSL against manual segmentation.. Neuroimage. 129:1-14.
Wimo A, Ballard C, Brayne C, Gauthier S, Handels R, Jones RW, Jonsson L, Khachaturian AS, Kramberger M.  2014.  Health economic evaluation of treatments for Alzheimer's disease: impact of new diagnostic criteria.. J Intern Med. 275(3):304-16.
Maria Rajah N, Wallace LMK, Ankudowich E, Yu EH, Swierkot A, Patel R, M Chakravarty M, Naumova D, Pruessner J, Joober R et al..  2017.  Family history and APOE4 risk for Alzheimer's disease impact the neural correlates of episodic memory by early midlife.. Neuroimage Clin. 14:760-774.

Pages